HighTower Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

HighTower Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-12,092	Closed	-$90K	–	2593
2020 Q3	$90K	Buy	+12,092	New	+$78.1K	﹤0.01%	2246
2020 Q1	–	Sell	-16,250	Closed	-$94K	–	2220
2019 Q4	$94K	Sell	16,250 -2,000	-11%	-$11.6K	﹤0.01%	2082
2019 Q3	$96K	Buy	18,250 +3,500	+24%	+$18.8K	﹤0.01%	2168
2019 Q2	$89K	Sell	14,750 -1,500	-9%	-$11.3K	﹤0.01%	2173
2019 Q1	$146K	Hold	16,250	–	–	﹤0.01%	2019
2018 Q4	$135K	Hold	16,250	–	–	﹤0.01%	1919
2018 Q3	$224K	Sell	16,250 -3,000	-16%	-$24.3K	﹤0.01%	1887
2018 Q2	$154K	Hold	19,250	–	–	﹤0.01%	1950
2018 Q1	$145K	Buy	19,250 +3,000	+18%	+$22.8K	﹤0.01%	1928
2017 Q4	$111K	Sell	16,250 -13,400	-45%	-$88.3K	﹤0.01%	2013
2017 Q3	$214K	Buy	+29,650	New	+$155K	﹤0.01%	1860

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

HighTower Advisors's ALDX Position: Q4 2020 in Review

HighTower Advisors sold out of Aldeyra Therapeutics (ALDX) in Q4 2020, closing a stake of 12,092 shares — an estimated $90K sold.

HighTower Advisors first reported a position in ALDX in Q3 2017 and held it in 11 quarters. The position peaked at $224K in Q3 2018. 98 funds tracked by Wall St. Rank hold ALDX as of Q4 2020.

HighTower Advisors reported no remaining Aldeyra Therapeutics position as of Q4 2020 after selling out during the quarter.
HighTower Advisors sold 12,092 Aldeyra Therapeutics shares in Q4 2020, an estimated $90K.
HighTower Advisors first reported a position in Aldeyra Therapeutics in Q3 2017 and held it in 11 quarters.
HighTower Advisors's Aldeyra Therapeutics position peaked at $224K in Q3 2018.
98 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.